Please login to the form below

Not currently logged in
Email:
Password:

Unlicensed sex drugs seized by MHRA

Enforcement officers from the UK's Medicines and Healthcare products Regulatory Agency seize nearly USD 709,263 worth of unlicensed medicines

Enforcement officers from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) have seized nearly GBP 350,000 (USD 709,263) worth of unlicensed medicines.

The drugs were discovered on 1 August 2007 at a secure lock-up facility in Uxbridge, West London and included Kamagra tablets and sachets, Lovegra and Apcalis, which are manufactured in India, but are unlicensed and untested despite claiming to treat male impotence. Investigations are ongoing.

Danny Lee-Frost, MHRA's head of criminal operations, said: ìThe type of medicines we seized cannot be guaranteed to be acceptably safe because they have not gone through the correct licensing regulatory process. At best these medicines could be a waste of money, at worst they could be severely detrimental to your health.î

If an individual is convicted of offences under the Medicines Act 1968, they can be sentenced to a maximum of two years imprisonment and/ or an unlimited fine. Where appropriate the MHRA will use the Proceeds of Crime Act 2002 to determine whether or not benefits were accrued through criminal activity and will recoup illicit earnings if the individual is found guilty.

7th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...
PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Iskra Reic
Leading AstraZeneca’s return to growth in Europe
PME talks to Iskra Reic, the company’s head of Europe and Canada...

Infographics